Diabetes mellitus medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
In hospitalized patients, [[Clinical practice guideline]]s are available by the [[American College of Physicians]] (ACP) recommends "Best Practice Advice 1: Clinicians should target a blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients. Best Practice Advice 2: Clinicians should avoid targets less than 7.8 mmol/L (<140mg/dL)"<ref name="pmid23709472">{{cite journal| author=Qaseem A, Chou R, Humphrey LL, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians| title=Inpatient Glycemic Control: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. | journal=Am J Med Qual | year= 2013 | volume= | issue= | pages= | pmid=23709472 | doi=10.1177/1062860613489339 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23709472 }} </ref> | In hospitalized patients, [[Clinical practice guideline]]s are available by the [[American College of Physicians]] (ACP) recommends "Best Practice Advice 1: Clinicians should target a blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients. Best Practice Advice 2: Clinicians should avoid targets less than 7.8 mmol/L (<140mg/dL)"<ref name="pmid23709472">{{cite journal| author=Qaseem A, Chou R, Humphrey LL, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians| title=Inpatient Glycemic Control: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. | journal=Am J Med Qual | year= 2013 | volume= | issue= | pages= | pmid=23709472 | doi=10.1177/1062860613489339 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23709472 }} </ref> | ||
===Insulin therapy for type 1 diabetes=== | |||
{|class="wikitable" | |||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''1.''' Most people with type 1 diabetes should be treated with multiple dose insulin (MDI) injections (three to four injections per day of basal and prandial insulin) or continuous sub- cutaneous insulin infusion (CSII). ''([[ADA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''2.''' Most people with type 1 diabetes should be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity. ''([[ADA guidelines classification scheme#Level of Evidence|Level of Evidence: E]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''3.''' Most people with type 1 diabetes should use insulin analogs to reduce hypoglycemia risk. ''([[ADA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="Seashell"|<nowiki>"</nowiki>'''3.''' Consider screening those with type 1 diabetes for other autoimmune dis- eases (thyroid, vitamin B12 deficiency, celiac) as appropriate. ''([[ADA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
==Management== | ==Management== | ||
Revision as of 20:36, 16 December 2013
|
Diabetes mellitus Main page |
|
Patient Information |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3] Karol Gema Hernandez, M.D. [4]
Medical Therapy
Diabetes mellitus is currently a chronic disease, without a cure, and medical emphasis must necessarily be on managing/avoiding possible short-term as well as long-term diabetes-related problems. There is an exceptionally important role for patient education, dietetic support, sensible exercise, self glucose monitoring, with the goal of keeping both short-term blood glucose levels, and long term levels as well, within acceptable bounds. Careful control is needed to reduce the risk of long term complications. This is theoretically achievable with combinations of diet, exercise and weight loss (type 2), various oral diabetic drugs (type 2 only), and insulin use (type 1 and increasingly for type 2 not responding to oral medications). In addition, given the associated higher risks of cardiovascular disease, lifestyle modifications should be undertaken to control blood pressure[1] and cholesterol by exercising more, smoking cessation, consuming an appropriate diet, wearing diabetic socks, and if necessary, taking any of several drugs to reduce pressure. Many Type 1 treatments include the combination use of regular or NPH insulin, and/or synthetic insulin analogs such as Humalog, Novolog or Apidra; the combination of Lantus/Levemir and Humalog, Novolog or Apidra. Another Type 1 treatment option is the use of the insulin pump with the some of most popular pump brands being: Cozmo, Animas, Medtronic Minimed, and Omnipod.
In countries using a general practitioner system, such as the United Kingdom, care may take place mainly outside hospitals, with hospital-based specialist care used only in case of complications, difficult blood sugar control, or research projects. In other circumstances, general practitioners and specialists share care of a patient in a team approach. Optometrists, podiatrists/chiropodists, dietitians, physiotherapists, clinical nurse specialists (eg, Certified Diabetes Educators and DSNs (Diabetic Specialist Nurse)), or nurse practitioners may jointly provide multidisciplinary expertise. In countries where patients must provide their own health care, the impact of out-of-pocket costs of diabetic care can be high. In addition to the medications and supplies needed, patients are often advised to receive regular consultation from a physician (e.g., at least every three to six months).
In hospitalized patients, Clinical practice guidelines are available by the American College of Physicians (ACP) recommends "Best Practice Advice 1: Clinicians should target a blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients. Best Practice Advice 2: Clinicians should avoid targets less than 7.8 mmol/L (<140mg/dL)"[2]
Insulin therapy for type 1 diabetes
| "1. Most people with type 1 diabetes should be treated with multiple dose insulin (MDI) injections (three to four injections per day of basal and prandial insulin) or continuous sub- cutaneous insulin infusion (CSII). (Level of Evidence: A)" |
| "2. Most people with type 1 diabetes should be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity. (Level of Evidence: E)" |
| "3. Most people with type 1 diabetes should use insulin analogs to reduce hypoglycemia risk. (Level of Evidence: A)" |
| "3. Consider screening those with type 1 diabetes for other autoimmune dis- eases (thyroid, vitamin B12 deficiency, celiac) as appropriate. (Level of Evidence: B)" |
Management
Diabetes management | Diabetic diet | Anti-diabetic drug | Conventional insulinotherapy | Intensive insulinotherapy
References
- ↑ Adler, A.I. (2000). "Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study". BMJ. 321 (7258): 412–419. ISSN 0959-8146. PMID 10938049. Unknown parameter
|coauthors=ignored (help) - ↑ Qaseem A, Chou R, Humphrey LL, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians (2013). "Inpatient Glycemic Control: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians". Am J Med Qual. doi:10.1177/1062860613489339. PMID 23709472.